“We are at an exciting time in the care of patients with cancer. We continue to have newer, better treatments – advancing our knowledge, enabling us to target these therapies more to each individual. At VCS you can be assured that you will receive state-of-the-art cancer care that is the best plan for you and your family.”
Work and Credentials:
Primary Location
Position
Medical Oncologist
Board Certification
Medical Oncology, Hematology and Internal Medicine
Fellowship
University of North Carolina Hospitals, Medical Oncology and Hematology
Residency
Rutgers Robert Wood Johnson Medical School
Medical School
Rutgers Robert Wood Johnson Medical School
College
Rutgers University
Dr. Timothy A. McCarthy graduated with high honors from Rutgers University where he received a Bachelor of Science in Materials Engineering. He then went on to earn his medical degree and complete an Internal Medicine residency at Rutgers Robert Wood Johnson Medical School. During his residency, Dr. McCarthy was honored with the Nilesh Tamakuwala, MD Memorial Award, a distinction presented to the individual who best demonstrated compassion in care and excellence in teaching.
Board-certified in Medical Oncology, Hematology and Internal Medicine, Dr. McCarthy completed his fellowship in Medical Oncology and Hematology at University of North Carolina Hospitals. As an Oncology Fellow, Dr. McCarthy took a leadership role working with various departments with a specific interest in quality and process improvement projects. Dr. McCarthy is a published author and has presented posters at various medical events, including the annual American Society of Clinical Oncology (ASCO) symposium.
Outside of medicine, Dr. McCarthy enjoys staying active and exploring the outdoors with his wife and 3 young children. He also enjoys listening to a diverse array of music and plays several different instruments.
Physician Video:
'
Physician Reviews:
Dr McCarthy was the best referral ever. I'm a very anxious overthinker when it comes to my health.. Dr McCarthy energy is soothing, calm and he embrace a great deal of patience. He is competent and honest. Thanks
Kind and friendly , patient to explain and he is the dr to take care of you with great results .
Dr. McCarthy takes the time to fully explain details, and is really appreciated.
I was diagnosed with long cancer and referred to Dr. McCarthy by my Pulmonologist "If I had cancer he is who I would go to". His office called me so we (and my husband) could meet and talk. I really appreciate this. I have another appointment next week where he will give me my treatment plan (he is presenting my case to the board of cancer specialists this Friday so they can come up with the best course of action. I have tremendous faith that I will receive the best care and treatment by a cancer specialist and the team he works with. Considering I have cancer, I consider myself so fortunate. I know this will go well.
Very helpful Excellent communications
Dr. McCarthy is super nice and He’s very understanding and listens to my concerns. He takes time with the patient to help them with their health issues! I highly recommend him to anyone looking for a specialist. Overall, I'm very pleased to have him as my Oncologist. Thank you Dr. McCarthy for being the dedicated, thoughtful, and compassionate doctor that you are! Had wonderful experience with him and the entile office staffs. Highly recommend this Doctor and his team at Fairfax location.
Physician Publications
January 1, 2016
Importance of pharmacokinetic studies in the management of acquired factor X deficiency
Read MoreClinical Trials (3)
Clinical Trial 20218
A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV NSCLC
Clinical Trial 20423
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination with Anti-PD-(L)1 Therapy in Subjects with NSCLC as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy
Clinical Trial 8951-CL-0103
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression
